HALO - Halozyme Therapeutics
This page shows which of the focused investors we track hold HALO and how their positions changed, so you can see how much conviction the group has in the stock.
In Q1 2026 it was held by 2 managers with an aggregate reported value of $2.73M, which is 0.00% of the combined portfolio.
As of Q1 2026, 2 tracked institutional managers held HALO (Halozyme Therapeutics) with an aggregate reported value of $2.73M — 0.00% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades HALO — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q1 2026
- Ticker
- HALO
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Torray Funds - Torray Funds | 0.36% | Add +0.1% | 38,179 | $2.47M |
| 2 | Richard Pzena - Pzena Investment Management | 0.00% | Reduce -5.3% | 4,049 | $261.69K |
Loading holder history for HALO…